-
1
-
-
41649086195
-
Regulating off-label drug use-rethinking the role of the FDA
-
Randall S, Stafford MD (2008) Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med 358:1427-1429
-
(2008)
N Engl J Med
, vol.358
, pp. 1427-1429
-
-
Randall, S.1
Stafford, M.D.2
-
2
-
-
79959947866
-
Off-label drug utilization in oncology
-
De Souza JA (2011) Off-label drug utilization in oncology. Clin Adv Hematol Oncol 9:473-475
-
(2011)
Clin Adv Hematol Oncol
, vol.9
, pp. 473-475
-
-
De Souza, J.A.1
-
3
-
-
0037249993
-
Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children
-
DOI 10.1093/annonc/mdg031
-
Conroy S, Newman C, Gudka S (2003) Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 14:42-47 (Pubitemid 36150257)
-
(2003)
Annals of Oncology
, vol.14
, Issue.1
, pp. 42-47
-
-
Conroy, S.1
Newman, C.2
Gudka, S.3
-
5
-
-
0036185967
-
Unlicensed and off-label drug use in children: Implications for safety
-
Choonara I, Conroy S (2002) Unlicensed and off-label drug use in children: implications for safety. Drug Saf 25:1-5 (Pubitemid 34208327)
-
(2002)
Drug Safety
, vol.25
, Issue.1
, pp. 1-5
-
-
Choonara, I.1
Conroy, S.2
-
6
-
-
0028950541
-
Off-label drug prescribing on a state university obstetric service
-
Rayburn WF, Turnbull GL (1995) Off-label drug prescribing on a state university obstetric service. J Reprod Med 40:186-188
-
(1995)
J Reprod Med
, vol.40
, pp. 186-188
-
-
Rayburn, W.F.1
Turnbull, G.L.2
-
8
-
-
0026006906
-
The off-label debate: A threat to the future of cancer care
-
Mortenson LE (1991) The off-label debate: a threat to the future of cancer care. Cancer Investig 9:597-599
-
(1991)
Cancer Investig
, vol.9
, pp. 597-599
-
-
Mortenson, L.E.1
-
9
-
-
33947313964
-
-
(Last Medical Review: March 14, 2011)
-
The American Cancer Society: Off-label drug use. Available at: http://www.cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/ Chemotherapy/off-label-drug-use. (Last Medical Review: March 14, 2011)
-
The American Cancer Society: Off-label Drug Use
-
-
-
10
-
-
20344384566
-
Évaluation des indications hors AMM chez des patients adultes traités par chimiothérapie anticancéreuse
-
Levêque D, Michallat AC, Schaller C, Ranc M (2005) Off label drug use in adult patients treated by anticancer chemotherapy. Bull Cancer 92:498-500 (Pubitemid 40852766)
-
(2005)
Bulletin du Cancer
, vol.92
, Issue.5
, pp. 498-500
-
-
Leveque, D.1
Michallat, A.C.2
Schaller, C.3
Ranc, M.4
-
11
-
-
2442511933
-
Off-label prescribing in oncology
-
DOI 10.1007/s00520-004-0593-6
-
Poole SG, Dooley MJ (2004) Off-label prescribing in oncology. Support Care Cancer 12:302-305 (Pubitemid 38647853)
-
(2004)
Supportive Care in Cancer
, vol.12
, Issue.5
, pp. 302-305
-
-
Poole, S.G.1
Dooley, M.J.2
-
12
-
-
84855166849
-
Off-label drug use in women with breast cancer
-
abstract 1016
-
Dean-Colombo W, Fang S, Smith W et al (2009) Off-label drug use in women with breast cancer. J Clin Oncol 27[15 suppl]:abstract 1016
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 SUPPL.
-
-
Dean-Colombo, W.1
Fang, S.2
Smith, W.3
-
13
-
-
0038182599
-
Effect of off-label use of oncology drugs on pharmaceutical costs: The rituximab experience
-
Kocs D, Fendrick AM (2003) Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 9:393-400 (Pubitemid 36617254)
-
(2003)
American Journal of Managed Care
, vol.9
, Issue.5
, pp. 393-400
-
-
Kocs, D.1
Fendrick, A.M.2
-
14
-
-
76349124677
-
Off-label prescription of antineoplastic drugs: An Italian prospective, observational, multi center survey
-
Roila F, Ballatori E, Labianca R et al (2009) Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multi center survey. Tumori 95:647-651
-
(2009)
Tumori
, vol.95
, pp. 647-651
-
-
Roila, F.1
Ballatori, E.2
Labianca, R.3
-
16
-
-
79957965504
-
Evaluation of oncology drugs at the European medicines agengy and US food and drug administration: When differences have an impact on clinical practice
-
Trotta F, Leufkens HGM, Schellens JHM et al (2011) Evaluation of oncology drugs at the European medicines agengy and US food and drug administration: when differences have an impact on clinical practice. J Clin Oncol 29:2266-2272
-
(2011)
J Clin Oncol
, vol.29
, pp. 2266-2272
-
-
Trotta, F.1
Leufkens, H.G.M.2
Schellens, J.H.M.3
-
17
-
-
59049104106
-
Rationing new medicines in the UK
-
Drummond M, Mason A (2009) Rationing new medicines in the UK. Br Med J 338:a3182
-
(2009)
Br Med J
, vol.338
-
-
Drummond, M.1
Mason, A.2
-
18
-
-
77954707651
-
Comparison of anticancer drug coverage decisions in the United States and United Kingdom: Does the evidence support the rhetoric?
-
Mason A, Drummond M, Ramsey S et al (2010) Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol 28:3234-3238
-
(2010)
J Clin Oncol
, vol.28
, pp. 3234-3238
-
-
Mason, A.1
Drummond, M.2
Ramsey, S.3
-
19
-
-
64049108287
-
Public funding of new cancer drugs: Is NICE getting nastier?
-
Mason AR, Drummond MF (2009) Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer 45:1188-1192
-
(2009)
Eur J Cancer
, vol.45
, pp. 1188-1192
-
-
Mason, A.R.1
Drummond, M.F.2
-
20
-
-
83255187283
-
A role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use, reply to letter
-
[Epub ahead of print]
-
Duran-Garcia E, Santos-Ramos B, Puigventos-Latorre F, Ortega (2011) A role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use, reply to letter. Int J Clin Pharm [Epub ahead of print]
-
(2011)
Int J Clin Pharm
-
-
Duran-Garcia, E.1
Santos-Ramos, B.2
Puigventos-Latorre, F.3
Ortega4
-
21
-
-
84864284204
-
-
Assises de médicament Groupe 3 "Encadrer les prescriptions hors AMM" Accessed 15 Sept 2011
-
Assises de médicament Groupe 3 "Encadrer les prescriptions hors AMM" (2011). Dispositifs dérogatoires de prescription "hors AMM". Available at: http://www.sante.gouv.fr/IMG/pdf/ Dispositifs-derogatoires-de-prescription-hors-AMM-.pdf Accessed 15 Sept 2011
-
(2011)
Dispositifs Dérogatoires de Prescription "hors AMM"
-
-
-
22
-
-
85052777310
-
-
Agenzia Italiana del Farmaco Accessed 15 Sept 2011
-
Agenzia Italiana del Farmaco (2007) Registro Farmaci Oncologici sottoposti a monitoraggio, Rapporto 2007. Available at http://antineoplastici. agenziafarmaco.it/Registro-farmaci.pdf Accessed 15 Sept 2011
-
(2007)
Registro Farmaci Oncologici Sottoposti a Monitoraggio, Rapporto 2007
-
-
-
23
-
-
34247362067
-
Reimbursement for cancer treatment: Coverage of off-label drug indications
-
American Society of Clinical Oncology
-
American Society of Clinical Oncology (2006) Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol 24:3206-3208
-
(2006)
J Clin Oncol
, vol.24
, pp. 3206-3208
-
-
-
24
-
-
54349129587
-
Off-label use of anticancer drugs
-
Levêque D (2008) Off-label use of anticancer drugs. Lancet Oncol 9:1102-1107
-
(2008)
Lancet Oncol
, vol.9
, pp. 1102-1107
-
-
Levêque, D.1
-
25
-
-
59749092456
-
Limits on Medicare's ability to control rising spending on cancer drugs
-
Bach PB (2009) Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633
-
(2009)
N Engl J Med
, vol.360
, pp. 626-633
-
-
Bach, P.B.1
-
26
-
-
77954651388
-
Uncertainty in assessing value of oncology treatments
-
Mullins CD, Montgomery R, Tunis R (2010) Uncertainty in assessing value of oncology treatments. Oncologist 15:58-64
-
(2010)
Oncologist
, vol.15
, pp. 58-64
-
-
Mullins, C.D.1
Montgomery, R.2
Tunis, R.3
-
27
-
-
33845429035
-
Off-label-use in der onkologie: Ein thema ohne ende?
-
DOI 10.1007/s00120-006-1223-3
-
Weißbach L, Riese J (2006) Off-label use in oncology: an inexhaustible topic? Urologe A 45(11):1410-1414 (Pubitemid 44900216)
-
(2006)
Urologe - Ausgabe A
, vol.45
, Issue.11
, pp. 1410-1414
-
-
Weissbach, L.1
Riese, J.2
-
28
-
-
0037146340
-
Demand grows for early access to promising cancer drugs
-
Baldwin J (2002) Demand grows for early access to promising cancer drugs. J Natl Cancer Inst 94:1668-1670
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1668-1670
-
-
Baldwin, J.1
-
29
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
DOI 10.1056/NEJMoa052122
-
Romond EH, Perez EA, Bryan J, Suman VJ et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 353:1673-1684 (Pubitemid 41464706)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.16
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer Jr., C.E.5
Davidson, N.E.6
Tan-Chiu, E.7
Martino, S.8
Paik, S.9
Kaufman, P.A.10
Swain, S.M.11
Pisansky, T.M.12
Fehrenbacher, L.13
Kutteh, L.A.14
Vogel, V.G.15
Visscher, D.W.16
Yothers, G.17
Jenkins, R.B.18
Brown, A.M.19
Dakhil, S.R.20
Mamounas, E.P.21
Lingle, W.L.22
Klein, P.M.23
Ingle, J.N.24
Wolmark, N.25
more..
-
30
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
DOI 10.1056/NEJMoa052306
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672 (Pubitemid 41464705)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.16
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
Gianni, L.7
Baselga, J.8
Bell, R.9
Jackisch, C.10
Cameron, D.11
Dowsett, M.12
Barrios, C.H.13
Steger, G.14
Huang, C.-S.15
Andersson, M.16
Inbar, M.17
Lichinitser, M.18
Lang, I.19
Nitz, U.20
Iwata, H.21
Thomssen, C.22
Lohrisch, C.23
Suter, T.M.24
Ruschoff, J.25
Suto, T.26
Greatorex, V.27
Ward, C.28
Straehle, C.29
McFadden, E.30
Dolci, M.S.31
Gelber, R.D.32
more..
-
31
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
32
-
-
63049099067
-
Use of 5-α-Reductase inhibitors for prostate cancer chemoprevention: American Society of clinical Oncology/American Urological association 2008 clinical practice guideline
-
Kramer BS, Hagerty KL, Justman S et al (2009) Use of 5-α-Reductase inhibitors for prostate cancer chemoprevention: American Society of clinical Oncology/American Urological association 2008 clinical practice guideline. J Clin Oncol 27:1502-1516
-
(2009)
J Clin Oncol
, vol.27
, pp. 1502-1516
-
-
Kramer, B.S.1
Hagerty, K.L.2
Justman, S.3
-
33
-
-
77950498003
-
Effect of dutasteride on the risk of prostate cancer
-
Andriole GL, Bostwick D, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202
-
(2010)
N Engl J Med
, vol.362
, pp. 1192-1202
-
-
Andriole, G.L.1
Bostwick, D.2
Brawley, O.W.3
-
34
-
-
37349006685
-
The off-label use of drugs in oncology: A position paper by the European Society for Medical Oncology (ESMO)
-
DOI 10.1093/annonc/mdm517
-
Casali PG (2007) The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 18:1923-1925 (Pubitemid 350286226)
-
(2007)
Annals of Oncology
, vol.18
, Issue.12
, pp. 1923-1925
-
-
Casali, P.G.1
-
35
-
-
33751404911
-
Off-label use of medicines: Consensus recommendations for evaluating appropriateness
-
Gazarian M, Kelly M, McPhee JR et al (2006) Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 185:544-548 (Pubitemid 44816941)
-
(2006)
Medical Journal of Australia
, vol.185
, Issue.10
, pp. 544-548
-
-
Gazarian, M.1
Kelly, M.2
McPhee, J.R.3
Graudins, L.V.4
Ward, R.L.5
Campbell, T.J.6
|